Navigation Links
Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease
Date:11/14/2007

On World COPD Day, Physicians Urged to Use Wider Screening Criteria for

Alpha-1 Antitrypsin Deficiency

KING OF PRUSSIA, Pa., Nov. 14 /PRNewswire/ -- A new study finds that a higher than expected number of COPD and severe asthma patients had abnormal low levels of alpha-1 antitrypsin (AAT), suggesting the need for broader criteria for AAT deficiency testing. AAT deficiency, also known as Alpha-1, is a widely undiagnosed hereditary disorder that is usually fatal in its severe form.

Alpha-1 is estimated to affect up to 100,000 Americans, but up to 95 percent are undiagnosed or have been misdiagnosed as having another form of chronic obstructive pulmonary disorder (COPD). Details of the study were presented at CHEST, the annual meeting of the American College of Chest Physicians held in Chicago from October 20 to 25. Study results are being announced today on World COPD Day to focus attention on the need for wider testing for AAT deficiency.

"Findings from this study suggest that simply all patients with moderate or severe persistent asthma and/or COPD with chronic pulmonary symptoms should be tested for AAT deficiency," said Gary Rachelefsky, MD, Professor of Allergy and Immunology and Director of the Executive Care Center for Asthma, Allergy and Respiratory Diseases at UCLA School of Medicine and study investigator. "It is imperative that clinicians become more vigilant about Alpha-1 testing as many patients are going undiagnosed or misdiagnosed due to screening criteria and practices."

The study, conducted by the Respiratory & Allergic Disease Foundation, recruited 40 office-based pulmonologists across the United States who tested 454 adult patients using the following simple screening criteria: persistent asthma and/or COPD patients with loss of lung function defined by either a FEV1 (forced expiratory volume at 1 second) or a ratio of FEV1 to forced vital capacity (FEV1/FVC) of less than 70 percent. Blood tests
'/>"/>

SOURCE CSL Behring
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014   Health 2.0 announces Bernard Tyson ... physicians Eric Topol , Patrick Soon-Shiong , and ... 2.0 8th Annual Fall Conference this coming Sept. 21-24 ... Health 2.0 is set to host the very first Wearable ... on Consumer Tech & Wearables: Powering Healthy Lifestyles. ...
(Date:7/29/2014)... July 29, 2014   ... study investigating the efficacy and safety of MSB0010718C in patients ... a rare and aggressive skin cancer lacking effective treatments   ... cohort Phase I clinical trial for the treatment of solid ... EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, ...
(Date:7/28/2014)... July 28, 2014  Dignity Health St. Mary,s ... the Get With The Guidelines®-Stroke Silver-Plus Quality Achievement ... by the American Heart Association/American Stroke Association for ... number four cause of death and a leading ... United States , according to the American ...
Breaking Medicine Technology:Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3
... , NEW YORK ... (Sony) announced today that it has acquired iCyt Mission Technology, Inc. ... cell and disease research, through its U.S. subsidiary, Sony Corporation of ... technologies to enter the flow cytometry business in the life science ...
... , Feb. 9 STD Med, Inc., a manufacturer ... is pleased to announce the acquisition of a new 32,000 sq. ... addition to the current footprint of 120,000 sq. ft. "We are ... financial times," said Steven Tallarida , President STD Med, "we ...
Cached Medicine Technology:Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 2Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 3STD Med Inc. Acquires Facility for Manufacturing and Start-Ups 2
(Date:7/29/2014)... Mountain View, CA (PRWEB) July 29, 2014 ... officially released a new product called BNatrl Silver ... said Lis Herrey, CEO and spokesperson for BNatrl LLC. ... and your loved ones from harmful pathogens and microbes.” ... renewable energy, and clean water products, with 10 percent ...
(Date:7/29/2014)... Regents Health Resources, a consulting firm traditionally ... care industry veteran Daryl Demonbreun and former St. Thomas ... company’s ambitious plans to grow into a full-service health ... along at a steady pace for nearly 20 years, ... says Bob Maier, founder and chief executive officer of ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 According ... Market by Type (Swipe And Area), Material (Optical ... Government, Defense, Healthcare, Commercial Security and Banking & ... to 2014 - 2020", published by MarketsandMarkets, the ... $14.35 Billion by 2020, growing at a high ...
(Date:7/29/2014)... This Latest Guidebook for Conducting Pharma Clinical ... not only provided a comprehensive and thorough knowledge of ... drug registration but also introduced the practical operation how ... to use the Chinese trial venues to keep drug ... by step. , The audiences of this guidebook are ...
(Date:7/29/2014)... There is controversy over how best to treat patients ... one wait until the cancer comes back or provide ... Now, a new study from Thomas Jefferson ... doctors and patients make a more informed decision. , ... says first author Robert Den, M.D., Assistant Professor of ...
Breaking Medicine News(10 mins):Health News:BNatrl Launches New Silver Solution Product 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Genomic analysis of prostate cancer indicates best course of action after surgery 2
... LANSING, Mich., Dec. 30 Neogen Corporation,(Nasdaq: NEOG ) announces the ... Quarter Results Webcast, When: Tuesday, January 6, 2009 ... How: Live over the Internet -- Simply log on to ... above., Contact: Terry Maynard of Neogen ...
... for Nearly 20% of 45 plus PopulationCHICAGO, Dec. 30 ... be your health. According to a recent AARP ... are suffering health problems due to financial stress. ... many Americans are facing because of the current economic ...
... - Stubbing Out Your 5 a Day Habit ... , Leading Child Trust Fund provider, ... decide,to give up smoking as their New Year,s resolution to ... futures. , According to figures from ...
... New Year,s resolutions often include being more careful, ... behavior, such as drug use. But new research ... seekers by psychologists--face an uphill battle in keeping ... their brains process dopamine. The research reveals that ...
... Committee for Quality,Assurance and the American Diabetes Association ... Barnett, M.D., Mirela Sturzu,M.D., Rudolf Teschan, M.D., and ... Recognition Program for providing quality care to,patients with ... and Zaki practice at the Aurora Health Center, ...
... CORONA, Calif., Dec. 29 Watson Pharmaceuticals,Inc. (NYSE: ... and specialty branded pharmaceuticals,today announced that its subsidiary, ... United States Food and Drug Administration on its,Abbreviated ... estradiol tablets USP, 0.15 mg / 0.02 mg. ...
Cached Medicine News:Health News:Economic Stress Taking Toll on Peoples' Health 2Health News:Urging New Year Quitters to Invest in Their Family's Futures 2Health News:Risk takers, drug abusers driven by decreased ability to process dopamine 2Health News:Aurora Physicians Receive National Recognition for Quality Diabetes Care 2Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R) 2
... NEAR-SkinT™ Incise Drapes have aggressive ... permeability for extended adhesion. It's made ... for unsurpassed conformability with allow-glare matte ... identification. , ,Available sterile in ...
The Quantum II Dual Wavelength Analyzer measures differential absorbances of liquid samples and converts those readings into analytical values....
... The HYBrite Hybridization System - the hands-free ... Procedures. Now performing fluorescent in situ hybridization ... ever before. HYBrite is the first rapid, ... FISH procedures. Now you can have a ...
... CELL-DYN 4000 uses the power of ... parameters to the hematology laboratory. Fluorescent ... random-access reticulocyte results. Fluorescent DNA staining ... accurate white blood cell values and ...
Medicine Products: